Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.
Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I, Davidenko I, Bondar V, Garin A, Boeck S, Ormanns S, Heinemann V, Bassi C, Evans TR, Andersson R, Hahn H, Picozzi V, Dicker A, Mann E, Voong C, Kaur P, Isaacson J, Allen A. Poplin E, et al. Among authors: ormanns s. J Clin Oncol. 2013 Dec 10;31(35):4453-61. doi: 10.1200/JCO.2013.51.0826. Epub 2013 Nov 12. J Clin Oncol. 2013. PMID: 24220555 Clinical Trial.
Translational research in pancreatic cancer: KRAS and beyond.
Boeck S, Ormanns S, Haas M, Bächmann S, Laubender RP, Siveke JT, Jung A, Kirchner T, Heinemann V. Boeck S, et al. Among authors: ormanns s. Pancreas. 2014 Jan;43(1):150-2. doi: 10.1097/MPA.0b013e31829629f6. Pancreas. 2014. PMID: 24326376 No abstract available.
Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
Ormanns S, Heinemann V, Raponi M, Isaacson J, Laubender RP, Haas M, Kruger S, Kleespies A, Mann E, Bartosiewicz M, Kirchner T, Boeck S. Ormanns S, et al. Eur J Cancer. 2014 Jul;50(11):1891-9. doi: 10.1016/j.ejca.2014.04.023. Epub 2014 May 20. Eur J Cancer. 2014. PMID: 24857044 Clinical Trial.
ALK expression is absent in pancreatic ductal adenocarcinoma.
Ormanns S, Assmann G, Reu S, Gallmeier E, Bader DC, Kleespies A, Haas M, Kruger S, Heinemann V, Kirchner T, Boeck S. Ormanns S, et al. J Cancer Res Clin Oncol. 2014 Sep;140(9):1625-8. doi: 10.1007/s00432-014-1774-4. Epub 2014 Jul 14. J Cancer Res Clin Oncol. 2014. PMID: 25017418
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104.
Ormanns S, Siveke JT, Heinemann V, Haas M, Sipos B, Schlitter AM, Esposito I, Jung A, Laubender RP, Kruger S, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR, Gauler TC, Märten A, Geissler M, Greten TF, Kirchner T, Boeck S. Ormanns S, et al. BMC Cancer. 2014 Aug 28;14:624. doi: 10.1186/1471-2407-14-624. BMC Cancer. 2014. PMID: 25164437 Free PMC article. Clinical Trial.
76 results